Nimble Therapeutics, formerly NimbleGen Systems, is developing an oral therapy that could treat psoriasis and inflammatory bowel disease.

Wisconsin State Journal

Madison

Dane County

Wisconsin

United States

AbbVie to acquire Madison-based Nimble Therapeutics for $200 million

All Sides

Media Bias/Fact Check

BIC has announced its acquisition of haircare company Tangle Teezer in a €200m (£165m) deal .   Headquartered in London, Tangle Teezer was first launched in 2007 as “the world’s first expertly designed detangling tool”.  The brand has amassed an estimated net sales worth more than €70m (£57m) in 2024, having doubled in size over the last four years.  According to Tangle Teezer, this demonstrates its ability to “establish leadership and build mar…

Retail Sector

BIC acquires Tangle Teezer in €200m deal

AbbVie agrees a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will add an oral peptide for psoriasis to its pipeline

Pharmaphorum

AbbVie adds psoriasis med with Nimble takeover

AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.

pharmaceutical-technology.com

AbbVie agrees to acquire Nimble Therapeutics for $200m

AbbVie Inc is a global biopharmaceutical company that specializes in the discovery, development, manufacturing, and marketing of advanced medicines. AbbVie focuses primarily on immunology, oncology, neuroscience, and virology treatments, and it has a broad portfolio of prescription drugs aimed at addressing a range of medical conditions. Humira (adalimumab), one of the world’s best-selling drugs, used to treat various autoimmune conditions. Howe…

See It Market

Why Investors Should Watch AbbVie Inc (ABBV)

Adds Nimble's lead asset and a pipeline of other novel oral peptide assets across autoimmune diseases.

contractpharma.com

AbbVie Agrees to Acquire Nimble Therapeutics

AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases. Additionally, AbbVie will acquire Nimble's

AbbVie to acquire Madison-based Nimble Therapeutics for $200 million

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics